Clinical Trials Logo

Recurrent Nasopharyngeal Undifferentiated Carcinoma clinical trials

View clinical trials related to Recurrent Nasopharyngeal Undifferentiated Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02794077 Active, not recruiting - Clinical trials for Recurrent Nasopharyngeal Undifferentiated Carcinoma

Cyclophosphamide for Nasopharyngeal Carcinoma

Start date: January 2008
Phase: Phase 2
Study type: Interventional

There is no standard third-line systemic treatment for inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). We investigated the efficacy and safety of metronomic oral cyclophosphamide as third-line treatment or beyond.

NCT ID: NCT00336063 Active, not recruiting - Clinical trials for Adult Nasal Type Extranodal NK/T-Cell Lymphoma

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Start date: March 3, 2006
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of vorinostat when given together with azacitidine in treating patients with nasopharyngeal cancer or nasal natural killer T-cell lymphoma that has recurred (come back) at or near the same place as the original (primary) tumor, usually after a period of time during which the cancer could not be detected or has spread to other parts of the body. Drugs used in chemotherapy, such as vorinostat and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vorinostat and azacitidine also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with azacitidine may kill more cancer cells.